Status:
COMPLETED
Prospective Study of TW in the Treatment of LN Type V With Gross Proteinuria
Lead Sponsor:
Nanjing University School of Medicine
Conditions:
Lupus Nephritis
Proteinuria
Eligibility:
All Genders
18-60 years
Phase:
NA
Brief Summary
The purpose of this study is to analyze the clinical effects and adverse reactions of tripterygium glycosides (TW) and CTX in LN-V patients with gross proteinuria.
Detailed Description
Compared with cyclophosphamide(CTX), to analyze the clinical effects and adverse reactions of tripterygium glycosides (TW) in LN-V patients with gross proteinuria.
Eligibility Criteria
Inclusion
- SLE patients aging 18-60 years, all of whom comply to the ISN/RPS classification.
- Urine protein≥3.0g/24h, Alb\<30g/L and Scr\<1.5mg/dL.
- All cases are type IV, confirmed by renal biopsy.
- All patients sign the informed consent and be willing to follow-up on time
Exclusion
- Accepted drug therapy, such as CTX MMF CsA FK506 or TW more than 2 weeks in the latest 3 months.
- Scr level above 1.5mg/dL, lasts more than 3 months.
- Heart, lung or central nervous systems involved or combined with severe infection.
- With liver function abnormal, ALT or AST being two times above the normal.
- Pregnant women or patients still in lactation.
Key Trial Info
Start Date :
April 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2011
Estimated Enrollment :
44 Patients enrolled
Trial Details
Trial ID
NCT00935389
Start Date
April 1 2009
End Date
May 1 2011
Last Update
August 2 2011
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Institute of Nephrology, Jinling Hospital
Nanjing, Jiangsu, China, 210002
2
Research Institute of Nephrology,Jinling Hospital
Nanjing, Jiangsu, China, 210002